VEGFA and non-small cell lung carcinoma: Using an antibody against VEGF/KDR complex (clone 11B5), one study reported VEGF/KDR-activated microvessel density as an important prognostic factor in NSCLC and that intense VEGF/KDR angiogenic pathway activation was associated with poor post-operative outcome in more than 50% of NSCLC cases [20].